Signatera Assessment in Early-Stage Endometrial Cancer

NCT ID: NCT07339384

Last Updated: 2026-01-22

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 1010 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-05-31
• Study Completion Date: 2034-05-31

Brief Summary

The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. The main question it aims to answer is:

• To evaluate if 3-year recurrence-free survival among women with Stage I, high-intermediate risk endometrial cancer who are ctDNA negative after receiving ctDNA-guided observation is non-inferior to adjuvant vaginal brachytherapy (an internal radiation therapy) Researchers will compare high-risk intermediate ctDNA negative participants who are observed to those who receive vaginal brachytherapy to see if they have similar outcomes.

Participants will be asked to:

• Receive serial ctDNA testing
• Visit their study doctor per their standard of care visits about every 3 months for 2 years
• Answer a questionnaire about their well-being

Detailed Description

This includes a randomized, multi-center, non-inferiority trial for a biomarker-defined subgroup, alongside two parallel, non-randomized exploratory cohorts. The study utilizes a biomarker-stratified design to formally test a treatment de-escalation strategy in patients with HIR endometrial cancer.

Following surgery, patients in the HIR cohort will be stratified based on post-operative circulating tumor DNA (ctDNA) status, as determined by the Signatera Genome assay. ctDNA-negative HIR Patients, based on the first valid post-operative ctDNA result within the baseline window, will be randomized (1:1) to either:

• Arm A: Observation unless ctDNA positivity within baseline window (<12 weeks), with serial ctDNA monitoring.
• Arm B: Vaginal brachytherapy (VBT) with serial ctDNA monitoring.

Following the initial baseline test, providers will be blinded to subsequent ctDNA results unless ctDNA positive within the first 12 weeks in Arm A [in which case, the provider will be notified and treatment of physician's choice (TPC) will be initiated. Initiation of TPC following ctDNA conversion is considered part of the ctDNA-guided treatment strategy, not a protocol deviation or cross-over, and such patients remain in the intent-to-treat population in Arm A]. Providers treating patients in Arm B will remain blinded to all ctDNA results after randomization. Post-operative ctDNA-Positive HIR patients will not be randomized and will continue serial testing while receiving TPC, which may include observation, radiation and/or chemotherapy. Providers and patients will be unblinded to the initial ctDNA result and blinded to ctDNA results thereafter.

The study will also include early stage low-risk (LR) and high-risk (HR) cohorts. Patients in these cohorts will not be randomized. They will continue serial ctDNA testing while receiving TPC, which may include observation, radiation and/or chemotherapy, and during surveillance. Providers and patients will be blinded to ctDNA results during the post-operative, TPC and surveillance period.

Conditions

Endometrial Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Observation

Participants will be monitored by their study physician and will not receive treatment

Group Type: OTHER

Signatera Genome ultra-sensitive ctDNA blood test

Intervention Type: DEVICE

Signatera Genome is intended for use as a post-surgical risk stratification tool for patients with early-stage HIR endometrial cancer. The test is used to identify patients with no evidence of MRD following definitive surgery.

Vaginal Brachytherapy (VBT)

Participants will receive standard-of-care vaginal brachytherapy

Group Type: ACTIVE_COMPARATOR

Signatera Genome ultra-sensitive ctDNA blood test

Intervention Type: DEVICE

Signatera Genome is intended for use as a post-surgical risk stratification tool for patients with early-stage HIR endometrial cancer. The test is used to identify patients with no evidence of MRD following definitive surgery.

Interventions

Signatera Genome ultra-sensitive ctDNA blood test

Signatera Genome is intended for use as a post-surgical risk stratification tool for patients with early-stage HIR endometrial cancer. The test is used to identify patients with no evidence of MRD following definitive surgery.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Signed and dated informed consent form (ICF) obtained prior to any trial-specific enrollment procedure.

2. Patient is ≥ 18 years-old at the time of ICF signature. 3. Able to submit sufficient residual tissue obtained per standard of care procedures.

HIR patients must meet all the following selection criteria to be eligible for the randomization cohort in the study. Eligibility will be assessed by the investigator:

1. FIGO 2009 Stage I after hysterectomy and lymph node assessment by bilateral pelvic lymphadenectomy or SLND

1. If para-aortic lymph nodes are not pathologically assessed, documentation of surgical assessment or imaging is recommended.

2. Stage I patients with endometrioid histology:

1. Age 70 years or older with one uterine risk factor,

2. Age 50-69 years with two risk factors,

3. Age 18 - 49 years with three risk factors.

Uterine risk factors include:

• Grade 2 or 3 tumor.
• Outer half depth of invasion.
• Lymphovascular invasion. Note: peritoneal cytology must be negative if performed.

Patients must meet all the following selection criteria to be eligible for the observation arms of the study. Eligibility will be assessed by the investigator following hysterectomy and lymph node assessment by bilateral pelvic and para-aortic lymphadenectomy or SLND:

1. High risk cohort

a. FIGO 2009 Stage I with high risk histology i. Defined as serous, clear cell, carcinosarcoma, or mixed histology.

1. Negative peritoneal cytology, where performed (recommended)

2. If para-aortic lymph nodes are not pathologically assessed, imaging is required b. FIGO 2009 Stage II Endometrioid

2. Low risk cohort

a. FIGO 2009 Stage I patients at low risk of recurrence i. Endometriod histology ii. Absent uterine risk factors, or present but insufficient to meet HIR criteria

Exclusion Criteria

Patients are not eligible for the study if they meet any of the following criteria, as assessed by the investigator:

1. Undifferentiated or dedifferentiated histology

2. Uterine sarcoma

3. Prior pelvic radiation therapy

4. Positive pelvic washings

5. Pelvic lymph node assessment was not performed

6. Isolated Tumor Cells (ITC) identified in the lymph node(s)

7. Prior therapy for endometrial cancer (including hormonal therapy, chemotherapy, targeted therapy, immunotherapy)

a. Contraceptives or other hormonal management for endometrial intraepithelial hyperplasia is allowed

8. Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of active malignancy within the last five years.

a. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.

9. Patients with a history of serious comorbid illness or uncontrolled illnesses that would preclude protocol therapy.

10. Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment.

11. Previous diagnosis of Crohn's disease or ulcerative colitis.

12. Patient is currently receiving, or plans to receive, commercial ctDNA/MRD assay for disease monitoring, excluding Signatera. Patients must agree to forego testing with assays other than Signatera Genome upon enrollment until end of study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Natera, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Adam ElNaggar, MD

Role: STUDY_DIRECTOR

Natera, Inc.

Central Contacts

Brooke Cormane, MBS

Role: CONTACT

bcormane@natera.com

844-778-4700

References

Firth, D. (1993). Bias reduction of maximum likelihood estimates. Biometrika, 80(1), 27-38

Reference Type: BACKGROUND

Mahdi H, Elshaikh MA, DeBenardo R, Munkarah A, Isrow D, Singh S, Waggoner S, Ali-Fehmi R, Morris RT, Harding J, Moslemi-Kebria M. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study. Gynecol Oncol. 2015 May;137(2):239-44. doi: 10.1016/j.ygyno.2015.01.544. Epub 2015 Jan 29.

Reference Type: BACKGROUND

PMID: 25641568 (View on PubMed)

Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, Lybeert ML, Slot A, Lutgens LC, Stenfert Kroese MC, Beerman H, van Lent M; postoperative Radiation Therapy in Endometrial Carcinoma Trial. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004 Apr 1;22(7):1234-41. doi: 10.1200/JCO.2004.08.159.

Reference Type: BACKGROUND

PMID: 15051771 (View on PubMed)

Proceedings of the International Conference on the Haemophilus, Actinobacillus and Pasteurella (HAP) Group of Organisms. June 1989. Can J Vet Res. 1990 Apr;54 Suppl:S1-82. No abstract available.

Reference Type: BACKGROUND

PMID: 2361201 (View on PubMed)

Siegenthaler F, Lindemann K, Epstein E, Rau TT, Nastic D, Ghaderi M, Rydberg F, Mueller MD, Carlson J, Imboden S. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification. Gynecol Oncol. 2022 May;165(2):230-238. doi: 10.1016/j.ygyno.2022.02.024. Epub 2022 Mar 8.

Reference Type: BACKGROUND

PMID: 35277281 (View on PubMed)

Lund L, Christiansen UB, Hansen IM, Funder VT. Carcinoma presenting as intrarenal haematoma, either spontaneously or after minor trauma. Int Urol Nephrol. 1994;26(5):497-500. doi: 10.1007/BF02767648.

Reference Type: BACKGROUND

PMID: 7860194 (View on PubMed)

Adib SM, Hajjar H, Lawand T. Cost and length-of-stay of hospital care billed to the Ministry of Public Health by private hospitals. J Med Liban. 1997;45(1):4-9.

Reference Type: BACKGROUND

PMID: 9421940 (View on PubMed)

Kemppainen TA, Kosma VM, Janatuinen EK, Julkunen RJ, Pikkarainen PH, Uusitupa MI. Nutritional status of newly diagnosed celiac disease patients before and after the institution of a celiac disease diet--association with the grade of mucosal villous atrophy. Am J Clin Nutr. 1998 Mar;67(3):482-7. doi: 10.1093/ajcn/67.3.482.

Reference Type: BACKGROUND

PMID: 9497194 (View on PubMed)

Curti HJ, Sanches PC, Jabur Filho M, Mazzoni CJ, Pasian S, Carvalhal SS. [Sudden death in a low socioeconomic population of the city of Campinas: anatomopathological study]. Arq Bras Cardiol. 1983 Aug;41(2):109-14. No abstract available. Portuguese.

Reference Type: BACKGROUND

PMID: 6675596 (View on PubMed)

Miteva L, Mitev V, Durmishev A. [The role of a growth-related cytosol protein kinase in the pathogenesis of psoriasis]. Eksp Med Morfol. 1994;32(3-4):19-26. Bulgarian.

Reference Type: BACKGROUND

PMID: 8857029 (View on PubMed)

https://seer.cancer.gov/csr/1975_2018/

Reference Type: BACKGROUND

Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2007 Jan;62(1):28-34; discussion 35-6. doi: 10.1016/j.crad.2006.06.015.

Reference Type: BACKGROUND

PMID: 17145260 (View on PubMed)

Howlader N, N.A., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds), SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. Bethesda, MD

Reference Type: BACKGROUND

Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45. doi: 10.3322/caac.21871. Epub 2025 Jan 16.

Reference Type: BACKGROUND

PMID: 39817679 (View on PubMed)

van den Heerik ASVM, Horeweg N, Creutzberg CL, Nout RA. Vaginal brachytherapy management of stage I and II endometrial cancer. Int J Gynecol Cancer. 2022 Mar;32(3):304-310. doi: 10.1136/ijgc-2021-002493.

Reference Type: BACKGROUND

PMID: 35256416 (View on PubMed)

Kako TD, Kamal MZ, Dholakia J, Scalise CB, Arend RC. High-intermediate risk endometrial cancer: moving toward a molecularly based risk assessment profile. Int J Clin Oncol. 2022 Feb;27(2):323-331. doi: 10.1007/s10147-021-02089-2. Epub 2022 Jan 17.

Reference Type: BACKGROUND

PMID: 35038071 (View on PubMed)

Other Identifiers

25-102-NCP

Identifier Type: -

Identifier Source: org_study_id